Free Trial

Cogent Biosciences (COGT) Competitors

Cogent Biosciences logo
$15.76 +1.01 (+6.85%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$16.14 +0.39 (+2.44%)
As of 10/3/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COGT vs. MRUS, TGTX, MENS, PTCT, KRYS, ACLX, ARWR, PCVX, ACAD, and PTGX

Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Merus (MRUS), TG Therapeutics (TGTX), Jyong Biotech (MENS), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arcellx (ACLX), Arrowhead Pharmaceuticals (ARWR), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

Cogent Biosciences vs. Its Competitors

Merus (NASDAQ:MRUS) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Merus has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Merus currently has a consensus target price of $92.88, indicating a potential downside of 1.50%. Cogent Biosciences has a consensus target price of $20.00, indicating a potential upside of 26.90%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Merus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merus
1 Sell rating(s)
12 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.18
Cogent Biosciences
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.77

96.1% of Merus shares are held by institutional investors. 3.7% of Merus shares are held by insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Merus had 57 more articles in the media than Cogent Biosciences. MarketBeat recorded 60 mentions for Merus and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.86 beat Merus' score of 0.24 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merus
10 Very Positive mention(s)
9 Positive mention(s)
24 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Cogent Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cogent Biosciences has a net margin of 0.00% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Merus-685.64% -50.28% -42.00%
Cogent Biosciences N/A -223.82%-89.44%

Merus has higher revenue and earnings than Cogent Biosciences. Merus is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$36.13M197.37-$215.33M-$5.50-17.14
Cogent BiosciencesN/AN/A-$255.86M-$1.78-8.85

Summary

Cogent Biosciences beats Merus on 9 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COGT vs. The Competition

MetricCogent BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.79B$3.36B$6.13B$10.58B
Dividend YieldN/A2.28%5.65%4.69%
P/E Ratio-8.8522.2886.9626.71
Price / SalesN/A458.33604.82131.77
Price / CashN/A47.8637.9061.31
Price / Book11.949.9312.556.55
Net Income-$255.86M-$52.80M$3.31B$277.50M
7 Day Performance11.30%5.22%4.28%2.42%
1 Month Performance20.77%10.61%6.90%8.63%
1 Year Performance41.85%25.03%70.54%31.60%

Cogent Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COGT
Cogent Biosciences
2.686 of 5 stars
$15.76
+6.8%
$20.00
+26.9%
+41.9%$1.79BN/A-8.8580
MRUS
Merus
1.1241 of 5 stars
$69.19
+1.4%
$90.54
+30.9%
+82.1%$5.16B$36.13M-12.5837Trending News
Analyst Downgrade
Options Volume
Analyst Revision
TGTX
TG Therapeutics
4.3897 of 5 stars
$34.97
+8.0%
$48.00
+37.3%
+65.1%$5.14B$329M94.51290
MENS
Jyong Biotech
N/A$59.53
-9.3%
N/AN/A$4.99BN/A0.0031High Trading Volume
PTCT
PTC Therapeutics
3.4237 of 5 stars
$60.85
+0.6%
$69.00
+13.4%
+86.2%$4.80B$806.78M8.731,410
KRYS
Krystal Biotech
4.6773 of 5 stars
$165.42
+1.1%
$209.00
+26.3%
+3.5%$4.73B$290.52M33.62210Positive News
ACLX
Arcellx
2.2263 of 5 stars
$78.22
+0.5%
$114.31
+46.1%
+8.7%$4.32B$107.94M-22.8780Insider Trade
ARWR
Arrowhead Pharmaceuticals
4.1691 of 5 stars
$32.05
+4.4%
$43.14
+34.6%
+91.9%$4.24B$3.55M-25.04400Insider Trade
PCVX
Vaxcyte
2.4646 of 5 stars
$33.47
+5.4%
$106.25
+217.4%
-61.7%$4.12BN/A-8.14160Positive News
ACAD
ACADIA Pharmaceuticals
4.4741 of 5 stars
$24.53
+0.5%
$29.65
+20.9%
+44.4%$4.12B$957.80M18.44510
PTGX
Protagonist Therapeutics
2.1551 of 5 stars
$64.51
+3.7%
$68.08
+5.5%
+46.1%$3.87B$434.43M92.16120Positive News

Related Companies and Tools


This page (NASDAQ:COGT) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners